CARY, N.C.--(BUSINESS WIRE)--Biologics, a limited distribution network partner for IMBRUVICA™ (ibrutinib), is pleased to announce the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA™ (ibrutinib) capsules as a single, oral agent for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. The drug was originally approved on November 13, 2013 for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Both indications are based on overall response rate. An improvement in survival or disease-related symptoms has not been established. Recommended dosing of IMBRUVICA™ for patients with CLL is 420 mg (three 140 mg capsules) orally once daily.
“We’re thrilled to continue to support patients who are in need of IMBRUVICA™ and look forward to seeing the impact this therapy will have on the CLL patient population,” said Dan Duffy, Chief Business Development Officer at Biologics.
Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. To send prescriptions via eScribe, physicians may search for Biologics within their EMR system.
• Pharmacy name: Biologics
• Street address: 120 Weston Oaks Court, Cary, NC 27513
• NCPDP: 3430369
• NPI: 1487640314
About Biologics: Biologics, Inc. is an oncology services company that empowers healthcare providers, payors and biopharma to optimize cancer care for the best possible outcomes – clinical, financial and emotional. Unifying fragmented healthcare services, Biologics brings efficiency and humanity to oncology care management by focusing on the patient’s best interest as the surest path to managing cost and risk. Encompassing patient access, specialty pharmacy and care integration services, the company has been recognized for its high-touch patient care model and clinical expertise in supporting complex care. Privately held, Biologics maintains headquarters and operations in Cary, North Carolina. To learn more, visit www.biologicsinc.com or follow us on Twitter (@BiologicsInc).